Latest news with #Omnipod®
Business Wire
08-07-2025
- Business
- Business Wire
Insulet to Announce Second Quarter 2025 Financial Results on August 7, 2025
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced it will report financial results for the second quarter of 2025 on August 7, 2025, before the opening of the financial markets. In connection with the release, management will host a conference call that day at 8:00 a.m. (Eastern Time). The link to the live call will be available on the Investor Relations section of the Company's website at 'Events and Presentations,' and will be archived for future replay. You may also access the live call by dialing (888) 770-7129 for domestic callers, or (929) 203-2109 for international callers, passcode is 5904836. About Insulet Corporation: Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet's flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit: or ©2025 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation. All rights reserved.
Business Wire
19-06-2025
- Health
- Business Wire
Insulet to Share Additional Evidence Demonstrating the Impact of Omnipod ® 5 on Improved Health Outcomes at the American Diabetes Association 85th Scientific Sessions
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced its planned activities during the American Diabetes Association (ADA) 85 th Scientific Sessions taking place June 20 – 23, 2025 at the McCormick Place Convention Center in Chicago, Illinois. 'We are thrilled to share more details that dive deeper into the clinical outcomes from our groundbreaking SECURE-T2D and RADIANT trials, as well as the real-world outcomes we are seeing, especially with type 2 diabetes,' said Dr. Trang Ly, MBBS, FRACP, PhD, Insulet Senior Vice President and Chief Medical Officer. 'We are also looking forward to many conversations with healthcare providers about what the outcomes mean, with practical insights on how to optimize therapy.' Insulet shared results of the first large pivotal trial of Automated Insulin Delivery (AID) in type 2 diabetes (SECURE-T2D) at last year's ADA conference. In March, Insulet presented results of the first randomized controlled trial to assess the direct transition from multiple daily injections (MDI) to AID in adults and children with type 1 diabetes not meeting glycemic targets with injections (RADIANT). Presentations at ADA this week will provide richer insights into both trials and more. Conference Activities: Dr. Ly will lead a panel discussion, ' Setting the Standard with Omnipod 5: Remarkable Results with Unmatched Simplicity, ' on Sunday, June 22 from 10:15 – 11:00 AM CT in the conference product theater. She will be joined by Dr. Anders L. Carlson, MD, Associate Executive Director, International Diabetes Center, Director, HealthPartners Diabetes Program, and Associate Professor, University of Minnesota Medical School; Dr. Gregory Forlenza, MD, MS, Associate Professor of Pediatrics, Director of Pediatric Diabetes Technology Research, Barbara Davis Center for Diabetes at the University of Colorado Anschutz Medical Campus; and Dr. Emma Wilmot, MB ChB BSc (hons), PhD, FRCP, Associate Professor, University of Nottingham, Honorary Consultant Diabetologist, University Hospitals of Derby and Burton NHS Trust, Royal Derby Hospital UK. They will have an interactive conversation around several thought-provoking case studies designed to challenge conventional thinking and therapeutic approaches. Dr. Ly will also provide a high-level overview of Insulet's innovation roadmap. Additionally, on Saturday, June 21, there will be a Diabetes Learning Byte session, ' Go Beyond GLP-1 Therapy in Type 2 Diabetes with Omnipod 5,' from 11:00 AM – 11:20 AM CT at booth 927 with Davida F. Kruger, MSN, APN-BC, BC-ADM, Certified Nurse Practitioner, Henry Ford Health Division of Endocrinology, Diabetes, Bone and Mineral Disease; and Leslie Barrett, MS, RD, CDCES, Director of Medical Affairs, Insulet. Oral Presentations Friday, June 20, Session: 5:30 – 6:30 PM CT, Presentation 5:45 – 6:00 PM CT (W184A-D) 130-OR– Real-World Glycemic Outcomes in Adults with Type 2 Diabetes (T2D) Using the Omnipod 5 Automated Insulin Delivery (AID) System with Dr. Sean Oser Saturday, June 21, Session: 1:30 – 3:00 PM CT, Presentation 2:00 – 2:15 PM CT (W185A-D) 155-OR– Reduced Perceived Diabetes Distress with the Omnipod 5 Automated Insulin Delivery (AID) System in Adults with Type 2 Diabetes (T2D) – Analysis of the SECURE-T2D Study with Dr. Kristin Castorino Monday, June 23, Session: 1:30 – 3:00 PM CT, Presentation 2:45 – 3:00 PM CT (W183A) 314-OR– Improved Outcomes Across Baseline Time-in-Range Levels with the Omnipod 5 AID System Compared with Multiple Daily Injections (MDI) in Type 1 Diabetes (T1D): Analysis of the RADIANT Study with Dr. Emma Wilmot Poster Presentations The following poster presentations will be held from 12:30 – 1:30 PM CT in the Poster Hall (Hall F1) during the weekend. Saturday, June 21 [945-P] – Improved Glycemic Outcomes with the Omnipod 5 AID System in Adults with Type 2 Diabetes (T2D) Previously Using Basal without Bolus Insulin: Sub-analysis of the SECURE-T2D Study with Dr. Anders Carlson [937-P] – Successful Transition from Multiple Daily Injections (MDI) to Automated Insulin Delivery (AID): Real-world Glycemic Outcomes among People with Diabetes Using the Omnipod AID System with Dr. Grazia Aleppo [958-P] – Impact of Insulin Therapy Technology on Health-Related Quality of Life in Adults with Type 1 Diabetes: A Health Utility Study of Five Forms of Therapy with Colin Hopley, MPH, Insulet Sunday, June 22 [2011-LB] – iPhone App Adoption Improves Bolusing Frequency in Adolescents and Young Adults with Type 1 Diabetes (T1D): Insights from Real-World Omnipod ® 5 Automated Insulin Delivery (AID) System Use with Dr. Gregory Forlenza Booth Activities: Podcast recordings for Beyond the Bolus, Within Range will be conducted from Insulet's booth (1218). Also, a Baird hosted webcast, ' ADA Recap Interview with Dr. Trang Ly, ' will be facilitated by Sr. Research Analyst, Jeff Johnson. This will take place on Monday, June 23, at 11:00 AM CT. The interview will feature a recap of highlights, new clinical data, and updates from ADA. A link to the webcast will be available on the Investor Relations section of the Company's website at under 'Events and Presentations,' and will be archived for future replay. Insulet will bring immersive booth experiences that showcase how Omnipod 5 is transforming diabetes management. Attendees can engage in hands-on demonstrations led by clinical experts, exploring optimization techniques that support better outcomes. Attendees can also play an educational trivia game to learn how Omnipod 5 brings a whole new level of simplicity and convenience for mealtime insulin dosing. Insulet will also be distributing a new comic book to celebrate representation for the diabetes community. Dyasonic: Sound of Strength featuring a hero with type 1 diabetes. To access the comic book and related materials go to About Insulet Corporation: Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet's flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit: and ©2025 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation. All rights reserved. All other trademarks are the property of their respective owners. The use of third-party trademarks does not constitute an endorsement or imply a relationship or other affiliation.
Yahoo
03-06-2025
- Business
- Yahoo
Kion Unveils New FinOps Governance Capabilities and Partnership with ProsperOps to Help Customers Maximize Cloud Value
New automation and policy capabilities empower FinOps teams to prevent waste, speed decision-making, and operate with confidence across multicloud SAN DIEGO, June 03, 2025--(BUSINESS WIRE)--FinOps X — Kion, the leading automated CloudOps platform for multicloud, today announced the release of Kion version 3.13 alongside a new partnership with ProsperOps, a leading FinOps optimization platform. Through the partnership with ProsperOps and new Kion FinOps governance platform upgrades, Kion helps organizations simplify spend and budgets for faster decision making, apply usage policies to prevent cloud waste and automate FinOps governance and policy to drive efficiency across multicloud infrastructure. Kion v3.13 offers new features that provide better chargeback capabilities, a revamped dashboard experience, more powerful enforcements and additional user driven enhancements that make the platform easier to use and deliver value faster. These enhancements provide CloudOps and FinOps teams with more control over spend, enables faster anomaly detection and delivers a streamlined user experience. One of the company's newest customers, Insulet, the innovative medical device manufacturer of the Omnipod® insulin delivery platform, highlighted their reasons for selecting Kion: "We needed a governance tool that could go beyond generic FinOps capabilities and provide clear, actionable insight into cloud spend so we could drive accountability across teams. Kion came at the perfect time, delivering a single workflow with forecasting and budgeting capabilities. It immediately helped surface waste and cost anomalies that used to take days to track down and shifted the conversation from reactive to proactive, automated cost control," said Matt Cofran, Director of Cloud Operations, Insulet. Meeting the Needs of Regulated EnterprisesAs a self-hosted platform, Kion is uniquely suited for government agencies and enterprises with complex compliance, data sovereignty and regulation requirements. The partnership with ProsperOps allows FinOps teams to shift from reactive cost control to strategic financial operations. Kion unifies governance, automation and FinOps in a policy-based platform that works with ProsperOps automation, integrating rate and workload optimization to reduce risks, cloud costs and manual effort. Together, the two platforms provide a well-rounded efficiency solution that is advantageous to government agencies and highly regulated industries seeking FinOps optimization controls while also needing to streamline compliance with stringent federal security and operational requirements. "FinOps governance and waste reduction are top priorities for businesses. Yet, cloud cost optimization is still a major challenge largely due to a lack of visibility, understanding and allocation of cloud resources and usage," said David Roldan, Head of Partnerships and Alliances at ProsperOps. "By partnering with Kion, we're able to bridge the FinOps and CloudOps gap, bringing together the best of both worlds — the automation for cloud cost savings with the policy driven governance that teams need to run efficiently and confidently in the cloud." "We say that the future of FinOps is CloudOps because of the rising priority of FinOps governance and policy at scale. A robust cloud operations platform will enable both teams to work together to manage their multicloud environment without spinning up unintentional resources or running over budget," said Tatum Tummins, Senior Product Manager at Kion. "Kion is well positioned to support the future of FinOps by forging fruitful partnerships and advancing our FinOps governance and automation capabilities to help regulated organizations maximize cloud value and deliver AI innovation faster." Kion was recently recognized as an IDC Innovator for FinOps and Cloud Cost Transparency. According to the report, "Kion was chosen as an innovator in the marketplace because of its commitment to supporting the growing and evolving cloud market." The report notes Kion's key differentiators as; comprehensive cloud governance to help companies rapidly mature their FinOps teams, visibility and advanced automation and customer service. In addition to exhibiting at FinOps X, Kion will be exhibiting at AWS Summit, Washington DC on June 10-11. Stop by Kion's booth #348 to learn more about common CloudOps challenges, benefits of integrating FinOps into your CloudOps practices and new Kion capabilities that drive cloud efficiency for public sector IT leaders. Tummins will also be onsite for a Lightning Talk on Tuesday, June 10 at 2:35pm ET in the Apollo Theater covering "FinOps ROI Playbook: Do More with Less to Maximize Cloud Efficiency." About KionKion automates CloudOps with a single platform providing policy-based identity, FinOps, and compliance for multicloud infrastructure. Kion helps organizations achieve 'governance by default' through improved visibility, automation, guardrails, and guidance across multicloud environments. This helps enterprises reduce complexity, eliminate chaos, and minimize manual work so they can innovate faster with less risk. Wherever they are on their cloud journey, Kion empowers organizations to confidently provision accounts, maintain financial control, and ensure compliance with security regulations. Kion serves leading commercial, higher education, and government agencies including Indeed, Verizon, NASA, and the Centers for Disease Control and Prevention (CDC). View source version on Contacts Media Contact Natalie Sasscer301-751-5176LaunchTech CommunicationsNsasscer@ Sign in to access your portfolio
Business Wire
03-06-2025
- Business
- Business Wire
Kion Unveils New FinOps Governance Capabilities and Partnership with ProsperOps to Help Customers Maximize Cloud Value
SAN DIEGO--(BUSINESS WIRE)-- FinOps X — Kion, the leading automated CloudOps platform for multicloud, today announced the release of Kion version 3.13 alongside a new partnership with ProsperOps, a leading FinOps optimization platform. Through the partnership with ProsperOps and new Kion FinOps governance platform upgrades, Kion helps organizations simplify spend and budgets for faster decision making, apply usage policies to prevent cloud waste and automate FinOps governance and policy to drive efficiency across multicloud infrastructure. Kion v3.13 offers new features that provide better chargeback capabilities, a revamped dashboard experience, more powerful enforcements and additional user driven enhancements that make the platform easier to use and deliver value faster. These enhancements provide CloudOps and FinOps teams with more control over spend, enables faster anomaly detection and delivers a streamlined user experience. One of the company's newest customers, Insulet, the innovative medical device manufacturer of the Omnipod® insulin delivery platform, highlighted their reasons for selecting Kion: 'We needed a governance tool that could go beyond generic FinOps capabilities and provide clear, actionable insight into cloud spend so we could drive accountability across teams. Kion came at the perfect time, delivering a single workflow with forecasting and budgeting capabilities. It immediately helped surface waste and cost anomalies that used to take days to track down and shifted the conversation from reactive to proactive, automated cost control,' said Matt Cofran, Director of Cloud Operations, Insulet. Meeting the Needs of Regulated Enterprises As a self-hosted platform, Kion is uniquely suited for government agencies and enterprises with complex compliance, data sovereignty and regulation requirements. The partnership with ProsperOps allows FinOps teams to shift from reactive cost control to strategic financial operations. Kion unifies governance, automation and FinOps in a policy-based platform that works with ProsperOps automation, integrating rate and workload optimization to reduce risks, cloud costs and manual effort. Together, the two platforms provide a well-rounded efficiency solution that is advantageous to government agencies and highly regulated industries seeking FinOps optimization controls while also needing to streamline compliance with stringent federal security and operational requirements. 'FinOps governance and waste reduction are top priorities for businesses. Yet, cloud cost optimization is still a major challenge largely due to a lack of visibility, understanding and allocation of cloud resources and usage,' said David Roldan, Head of Partnerships and Alliances at ProsperOps. 'By partnering with Kion, we're able to bridge the FinOps and CloudOps gap, bringing together the best of both worlds — the automation for cloud cost savings with the policy driven governance that teams need to run efficiently and confidently in the cloud.' "We say that the future of FinOps is CloudOps because of the rising priority of FinOps governance and policy at scale. A robust cloud operations platform will enable both teams to work together to manage their multicloud environment without spinning up unintentional resources or running over budget,' said Tatum Tummins, Senior Product Manager at Kion. 'Kion is well positioned to support the future of FinOps by forging fruitful partnerships and advancing our FinOps governance and automation capabilities to help regulated organizations maximize cloud value and deliver AI innovation faster.' Kion was recently recognized as an IDC Innovator for FinOps and Cloud Cost Transparency. According to the report, 'Kion was chosen as an innovator in the marketplace because of its commitment to supporting the growing and evolving cloud market.' The report notes Kion's key differentiators as; comprehensive cloud governance to help companies rapidly mature their FinOps teams, visibility and advanced automation and customer service. In addition to exhibiting at FinOps X, Kion will be exhibiting at AWS Summit, Washington DC on June 10-11. Stop by Kion's booth #348 to learn more about common CloudOps challenges, benefits of integrating FinOps into your CloudOps practices and new Kion capabilities that drive cloud efficiency for public sector IT leaders. Tummins will also be onsite for a Lightning Talk on Tuesday, June 10 at 2:35pm ET in the Apollo Theater covering 'FinOps ROI Playbook: Do More with Less to Maximize Cloud Efficiency.' About Kion Kion automates CloudOps with a single platform providing policy-based identity, FinOps, and compliance for multicloud infrastructure. Kion helps organizations achieve 'governance by default' through improved visibility, automation, guardrails, and guidance across multicloud environments. This helps enterprises reduce complexity, eliminate chaos, and minimize manual work so they can innovate faster with less risk. Wherever they are on their cloud journey, Kion empowers organizations to confidently provision accounts, maintain financial control, and ensure compliance with security regulations. Kion serves leading commercial, higher education, and government agencies including Indeed, Verizon, NASA, and the Centers for Disease Control and Prevention (CDC).
Business Wire
23-05-2025
- Business
- Business Wire
Insulet to Present at the Goldman Sachs 46 th Annual Global Healthcare Conference 2025
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced that management will present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 in Miami on Tuesday, June 10, 2025 at 9:20 a.m. (Eastern Time). To listen to the live audio webcast of the presentation, please visit A replay of the webcast will also be available following the event. About Insulet Corporation: Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet's flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit or ©2025 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation. All rights reserved.
